Second malignant neoplasms following hematopoietic stem cell transplantation.

University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
International Journal of Hematology (Impact Factor: 1.68). 05/2004; 79(3):229-34. DOI: 10.1532/IJH97.03178
Source: PubMed

ABSTRACT Hematopoietic stem cell transplantation is being successfully used to treat a variety of malignant and nonmalignant disorders. This therapy has resulted in an increasing number of survivors who are at risk for adverse long-term outcomes, including the development of second and subsequent malignant neoplasms. We review the incidence and spectrum of posttransplantation malignancies and discuss risk factors and future directions for research.

  • Source
    Journal of Clinical Oncology 07/2009; 27(24):e62-4. · 17.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Using stem cell-conditioned medium (CM) might be a viable alternative to stem cell transplantation, which is often hampered by low grafting efficiency and potential tumorigenesis, but the concentrations of angiogenic growth factors in CM are too low for therapeutic use and some components of the medium are not for human use. We used 3D spheroid culture of human adipose-derived stem cells (hADSCs) with clinically relevant medium (CRM) composed of amino acids, vitamins, glucose, and human serum to produce clinically relevant CM containing angiogenic and/or anti-apoptotic factors such as VEGF, FGF2, HGF, and CXCL12. The concentration of these factors was 23- to 27-fold higher than that in CM produced by conventional monolayer culture. Compared to injection of either monolayer culture CM or hADSC, injection of spheroid culture CM to an ischemic region in mice significantly enhanced endothelial cell growth, CD34(+)/PTPRC(-) (endothelial progenitor) cell mobilization from bone marrow, and bone marrow cell homing to the ischemic region, resulting in improved blood vessel density, limb salvage, and blood perfusion in a mouse hindlimb ischemia model. The stem cell-CM developed in this study will likely be an effective alternative to conventional stem cell transplantation therapy.Molecular Therapy (2014); doi:10.1038/mt.2013.301.
    Molecular Therapy 01/2014; · 6.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic cell transplantation (HCT) offers potentially curative therapy for numerous malignancies, as well as immunologic, hematologic and metabolic disorders. While many patients are cured of their primary disease, a proportion develops posttransplant (secondary) malignant neoplasms (SMN) [2, 19, 29]. Individuals treated with HCT may have been exposed to pre-transplant chemotherapy or radiotherapy, then to additional cytotoxic therapy as part of the preparative regimen for transplantation, and eventually, to immune suppression. All of these factors may act alone or in concert to increase the risk for SMNs. Patients may also be innately cancer susceptible and have a genetic predisposition towards multiple primary malignancies. Potential risk factors for SMN following hematopoietic stem cell transplantation are listed in Tables 14.1 and 14.2. Table 14.1.General risk factors for post-transplant malignancies Table 14.2.Post-transplant SMN specific risk factors
    03/2010: pages 155-162;